UiPath (PATH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

It's still too early to say whether UiPath will ultimately end up, on net, as benefitting from or being harmed by AI adoption. Read why PATH stock is a Sell.

PATH heads into Q4 earnings with revenues seen rising 9.7%, but weak stock momentum and neutral earnings signals leave investors weighing a hold stance.

UiPath (PATH) delivered earnings and revenue surprises of +20.00% and +3.50%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?

UiPath Inc. shares were on track for their worst daily drop on record after the automation-software company’s latest earnings marked a twist on the industry’s well-established doldrums. Software ...

UiPath’s blended fair value estimate has been trimmed from US$16.19 to US$15.93, a move that sits alongside bullish analyst price targets up to US$18 and recent target cuts from more cautious voices.

UiPath (PATH) closed at $11.86 in the latest trading session, marking a +2.68% move from the prior day. This move outpaced the S&P 500's daily loss of 1.33%. Elsewhere, the Dow saw a downswing of 0.95 ...

The company's expenses and the sudden resignation of its CEO are concerning. Yet, UiPath appears to have more going for it than its stock price may indicate. However, the robotics stock may have hit ...

UiPath launches AI-based Medical Record Summarization tool, reducing processing time from 45 minutes to minutes. Powered by Google Cloud, the agent improves accuracy, saves 40 minutes per referral, ...